X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2602) 2602
Publication (168) 168
Book Review (35) 35
Book Chapter (7) 7
Magazine Article (6) 6
Newsletter (2) 2
Newspaper Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2371) 2371
enoxaparin (1518) 1518
female (1448) 1448
male (1295) 1295
index medicus (1153) 1153
anticoagulants - adverse effects (1086) 1086
aged (1039) 1039
middle aged (1026) 1026
anticoagulants - therapeutic use (924) 924
enoxaparin - adverse effects (912) 912
enoxaparin - therapeutic use (770) 770
prevention (697) 697
venous thromboembolism (680) 680
anticoagulants - administration & dosage (652) 652
adult (642) 642
treatment outcome (635) 635
enoxaparin - administration & dosage (608) 608
molecular-weight heparin (586) 586
anticoagulants (542) 542
risk factors (540) 540
hematology (509) 509
hemorrhage - chemically induced (504) 504
thromboembolism (468) 468
surgery (465) 465
peripheral vascular disease (435) 435
unfractionated heparin (425) 425
heparin (404) 404
venous thromboembolism - prevention & control (401) 401
aged, 80 and over (398) 398
deep-vein thrombosis (381) 381
thromboprophylaxis (378) 378
thrombosis (378) 378
venous thrombosis - prevention & control (330) 330
prophylaxis (323) 323
cardiac & cardiovascular systems (322) 322
pharmacology & pharmacy (318) 318
drug therapy (303) 303
retrospective studies (299) 299
medicine, general & internal (293) 293
rivaroxaban (285) 285
heparin - adverse effects (284) 284
prospective studies (284) 284
postoperative complications - prevention & control (281) 281
heparin, low-molecular-weight - therapeutic use (272) 272
thromboembolism - prevention & control (269) 269
heparin, low-molecular-weight - adverse effects (257) 257
warfarin (255) 255
time factors (247) 247
fibrinolytic agents - adverse effects (243) 243
fibrinolytic agents - therapeutic use (238) 238
heparin - therapeutic use (229) 229
venous thromboembolism - etiology (229) 229
drug administration schedule (219) 219
risk assessment (219) 219
therapy (215) 215
abridged index medicus (208) 208
pulmonary-embolism (206) 206
administration, oral (202) 202
arthroplasty, replacement, knee - adverse effects (198) 198
double-blind (198) 198
risk (197) 197
anticoagulation (193) 193
arthroplasty, replacement, hip - adverse effects (190) 190
venous thrombosis - etiology (190) 190
double-blind method (189) 189
dose-response relationship, drug (185) 185
factor xa inhibitors (185) 185
randomized controlled trials as topic (185) 185
trial (183) 183
fibrinolytic agents - administration & dosage (180) 180
medicine & public health (178) 178
health aspects (177) 177
orthopedics (175) 175
incidence (173) 173
pulmonary embolism (173) 173
dosage and administration (171) 171
heparin, low-molecular-weight - administration & dosage (170) 170
venous thrombosis (170) 170
care and treatment (168) 168
low-molecular-weight heparin (168) 168
safety (168) 168
fondaparinux (166) 166
injections, subcutaneous (166) 166
pulmonary embolism - prevention & control (158) 158
thrombosis - prevention & control (158) 158
complications (157) 157
management (157) 157
drug therapy, combination (156) 156
arthroplasty (154) 154
analysis (153) 153
pregnancy (153) 153
adolescent (152) 152
venous thrombosis - drug therapy (152) 152
follow-up studies (150) 150
replacement (150) 150
heparin - administration & dosage (148) 148
aspirin (145) 145
hemorrhage (144) 144
acute coronary syndromes (143) 143
pharmacokinetics (143) 143
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2470) 2470
German (39) 39
Spanish (35) 35
French (28) 28
Russian (13) 13
Italian (6) 6
Norwegian (5) 5
Polish (5) 5
Portuguese (4) 4
Serbian (4) 4
Chinese (3) 3
Czech (2) 2
Danish (2) 2
Turkish (2) 2
Croatian (1) 1
Hebrew (1) 1
Japanese (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | THERAPY | DISEASE | PREVENTION | DEEP-VEIN THROMBOSIS | IDRAPARINUX | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article